---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-024176"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T10:02:25.694625+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix submits IND for PUR3100 Phase 2 trial in acute migraine

## Summary
- IND submitted to FDA for PUR3100, an inhaled dry powder DHE formulation for acute migraine.
- Phase 1 data showed PK similar to IV DHE with fewer side effects.
- Phase 2 protocol investigates safety and preliminary efficacy in migraine patients.
- Approximately 40 million U.S. patients with acute migraine need additional options.
- PUR3100 uses proprietary iSPERSE dry powder delivery technology.

## SEC filing metadata
- accession: 0001493152-23-024176
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315223024176/0001493152-23-024176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315223024176/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-024176
- JSON: https://secwatch.observer/filing/0001493152-23-024176.json
- Plain text: https://secwatch.observer/filing/0001493152-23-024176.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.